Proposal to incorporate the guidance into a clinical guideline

The planned date for review of the above guidance was November 2014.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full appraisal review.

No new evidence has been found that would lead to a change in the existing recommendations made in TA268, so an update of the guidance is not required. However, NICE is currently developing a clinical guideline for the assessment and management of melanoma, and it was indicated in the draft scope that TA268 should be incorporated into the forthcoming guideline.

As a result, we believe that TA268 should be incorporated into the forthcoming clinical guideline for melanoma. TA268 will be moved to the static list and will remain extant when the guideline is published.  This has the consequence of preserving the funding direction, and the Patient Access Scheme for ipilimumab will remain in place.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted. 

January 2015

Attachments